
Please try another search
Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and is based in Montpellier, France.
Name | Age | Since | Title |
---|---|---|---|
Cecilia Marelli | - | 2023 | Member of Scientific Advisory board |
Walt A. Linscott | - | - | Supervisory Board Member |
Claudio Cuello | - | - | Member of International Scientific Advisory Board - Neuro-Psychiatry |
George Lyketsos | - | 2023 | Member of Scientific Advisory Board |
Bernard Connes | - | 2019 | Member of the Supervisory Board |
Paul Loubet | - | - | Member of International Scientific Advisory Board - Infectious diseases |
Mahmoud Pouladi | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review